AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in this application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended). A plasmid expression vector ~~polynucleotide~~ which induces anti-HSV antibodies or protective immune responses upon introduction into vertebrate tissue, wherein said vector ~~polynucleotide~~ comprises at least one gene encoding at least one HSV protein or truncated protein, said gene or genes being operably linked to a transcription promoter.

Claim 2. (Currently Amended). The plasmid expression vector ~~polynucleotide~~ of Claim 1, wherein said gene encodes an HSV protein selected from a group consisting of gB, gC, gD, gH, gL, ICP27 and truncated gB.

Claim 3. (Currently Amended). The plasmid expression vector ~~polynucleotide~~ of Claim 1 wherein said gene encodes a carboxy-terminal truncated gB protein.

Claim 4. (Currently Amended). The plasmid expression vector ~~polynucleotide~~ of Claim 3 wherein said truncated gB deletion comprises the amino terminal 707 amino acids of wild type gB.

Claim 5. (Currently Amended). The plasmid expression vector ~~polynucleotide~~ of Claim 4 which is V1Jns:ΔgB.

Claim 6. (Currently Amended). The plasmid expression vector ~~polynucleotide~~ of Claim 2 wherein said gene encodes the HSV protein, gD.

Claim 7. (Currently Amended). The plasmid expression vector ~~polynucleotide~~ of Claim 6 which is V1Jns:gD.

Claim 8. (Currently Amended). A vaccine for inducing an immune response against HSV which comprises a first plasmid expression vector ~~polynucleotide~~ which expresses the HSV

protein gD and a second plasmid expression vector ~~polynucleotide~~ which expresses a carboxy-terminal truncated gB protein.

Claim 9. (Currently Amended). A vaccine of claim 8 wherein said first plasmid expression vector ~~polynucleotide~~ is V1Jns:gD.

Claim 10. (Currently Amended). A vaccine of claim 8 wherein said second plasmid expression vector ~~polynucleotide~~ is V1Jns:ΔgB.

Claim 11. (Currently Amended). A vaccine of claim 10 wherein said first plasmid expression vector ~~polynucleotide~~ is V1Jns:gD.

Claim 12. (Previously Presented). A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the vaccine according to Claim 11 into a tissue of a vertebrate.

Claim 13. (Currently Amended). A vaccine for inducing immune responses against HSV which comprises the plasmid expression vector ~~polynucleotide~~ of Claim 11 and a pharmaceutically acceptable carrier.

Claim 14. (New). A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the plasmid expression vector according to Claim 1 into a tissue of a vertebrate.

Claim 15. (New). A vaccine for inducing immune responses against HSV which comprises the plasmid expression vector of Claim 1 and a pharmaceutically acceptable carrier.

Claim 16. (New). A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the plasmid expression vector according to Claim 2 into a tissue of a vertebrate.

Claim 17. (New). A vaccine for inducing immune responses against HSV which comprises the plasmid expression vector of Claim 2 and a pharmaceutically acceptable carrier.